Merkel Cell Carcinoma (MCC) is a rare but aggressive form of skin cancer that typically appears as painless, flesh-colored or bluish-red nodules on the skin. Although it accounts for less than 1% of skin cancers, its rapid growth and tendency to metastasize make it challenging to treat. Cancer research in MCC focuses on understanding its molecular pathways and developing targeted therapies. Recent advances include the identification of Merkel cell polyomavirus (MCV) as a potential causative agent, leading to the development of immunotherapies such as checkpoint inhibitors. Additionally, efforts are underway to explore combination therapies and biomarkers for early detection and personalized treatment approaches. Despite progress, further research is needed to improve outcomes for patients with this aggressive malignancy.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China